Answers are grounded in this paper and cite their sources.
Most real-world data on CGRP mAbs have been published from high-income countries such as the USA, Western countries, Japan, Korea, and Singapore. However, data from low- and middle-income countries in Southeast Asia is lacking. This is the first real-world study from Thailand to describe the efficacy of CGRP mAbs therapy in migraine patients and to analyze the response trends between episodic migraine and chronic migraine.
No takes yet. Share an insight, caveat, or question.
Anukoolwittaya et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: